Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 2 1

Status

Completed 5

Sponsor Class

NIH 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Sarcoma 5CNS 5

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Lymphoma, Non-Hodgkin 16Myelodysplastic Syndromes 15Leukemia, Myeloid, Acute 15Leukemia, Lymphocytic, Chronic, B-Cell 15Hodgkin Disease 15Lymphoma, Mantle-Cell 14Multiple Myeloma 13Waldenstrom Macroglobulinemia 12Graft vs Host Disease 12Lymphoma, Large B-Cell, Diffuse 11Lymphoma 11Leukemia 11Lymphoma, Follicular 10Lymphoma, B-Cell, Marginal Zone 10Sarcoma 9Myeloproliferative Disorders 9Burkitt Lymphoma 9Tuberous Sclerosis 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Primary Myelofibrosis 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Neoplasms 6Lymphoma, Large-Cell, Immunoblastic 6Leukemia, Myelomonocytic, Chronic 6Congenital Abnormalities 6Breast Neoplasms 6Myelodysplastic-Myeloproliferative Diseases 5Lymphoma, Large-Cell, Anaplastic 5Lymphangioleiomyomatosis 5

Interventions

Temozolomide 115Bevacizumab 72Radiotherapy 52Radiation 23Erlotinib Hydrochloride 13Lomustine 12pembrolizumab 11Magnetic Resonance Spectroscopy 11Vorinostat 10Nivolumab 10Surgical Procedures, Operative 9Irinotecan 9Sorafenib 8Radiotherapy, Intensity-Modulated 8Radiotherapy, Conformal 7Immunoglobulin G 7Everolimus 7Drug Therapy 7Disulfides 7Radiosurgery 6Granulocyte-Macrophage Colony-Stimulating Factor 6Carmustine 6antineoplaston AS 2-1 5antineoplaston A10 5Sirolimus 5Cilengitide 5veliparib 4veledimex 4temsirolimus 4selinexor 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Has results × Glioblastoma × Sirolimus × Clear all
NCT01051557 2021-07-19

Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma

National Cancer Institute (NCI)

Phase 1/2 Completed
36 enrolled 15 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

NCT00329719 2018-10-16

Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma

National Cancer Institute (NCI)

Phase 1/2 Completed
115 enrolled 13 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT00335764 2018-07-02

Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

National Cancer Institute (NCI)

Phase 1/2 Completed
92 enrolled 24 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT00112736 2015-06-15

Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma

National Cancer Institute (NCI)

Phase 1/2 Completed
69 enrolled 12 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

NCT00672243 2013-08-07

Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme

Duke University

Phase 2 Completed
32 enrolled 13 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡